The biology of 3-iodothyronamine...Riccardo Zucchi University of Pisa, Italy The biology of...
Transcript of The biology of 3-iodothyronamine...Riccardo Zucchi University of Pisa, Italy The biology of...
Riccardo ZucchiUniversity of Pisa, Italy
The biology of 3-iodothyronamine
83rd ATA Annual Meeting – Puerto Rico, October 17, 2013
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Disclosure
Nothing to disclose
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
3-Iodothyronamine (T1AM)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM as a chemical messenger
• found in brain and other tissues
• agonist of TAAR1• interacts with amine transporters• interacts with mitochondrial targets• interacts with apoB-100
• hypothermia• decreased cardiac contractility• decreased insulin secretion• increased gluconeogenesis• shift to lipid catabolism• neuromodulatory action• behavioral effects
• endogenous compound, which
• by acting on specific receptors
• produces functional effects
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
0
1.0e5In
tens
ity, c
ps
A1.0e4
0
B
0
1.5e5C
4.0Time, min2.00
4.1e5E
4.0Time, m in2.00
5.6e4F
Inte
nsity
, cps
4.0Time, m in2.00
2.2e4G
Inte
nsity
, cps
0
3363D
T1AM
D 4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
D 4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
T1AM
0
1.0e5In
tens
ity, c
ps
A1.0e4
0
B
0
1.5e5C
4.0Time, min2.00
4.1e5E
4.0Time, m in2.00
5.6e4F
Inte
nsity
, cps
4.0Time, m in2.00
2.2e4G
Inte
nsity
, cps
0
3363D
T1AM
D 4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
D 4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
T1AM
D4-T1AM
T1AMliver
kidney muscle
heart
stomach
lung
serum
T1AM assay in rat tissues
Saba et al, Endocrinology 151:5063, 2010
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM T3 T4
Serum (nM) 0.3±0.1 1.4±0.1 49.6±4.8Heart 6.6±1.4 0.5±0.1 0.7±0.2Liver 92.9±28.4 4.7±0.8 14.5±3.0Kidney 36.1±10.4 7.1±0.9 13.0±2.8Muscle 25.0±6.9 0.8±0.2 1.8±0.4Stomach 15.5±6.9 3.3±0.7 16.0±9.2Lung 5.6±1.5 4.4±1.5 24.8±12.2
T1AM concentration in rat tissues (pmol/g)
Saba et al, Endocrinology 151:5063, 2010
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Tissue distribution of [125I]-T1AM in mouse
30 min
adip
ose
t.bl
ood
bone
brai
nga
llbla
dder
hear
tin
test
ine
kidn
eyliv
erlu
ngm
uscl
epa
ncre
assk
insp
leen
stom
ach
thyr
oid
0
10
20
30
*
**
**
* *
radi
oact
ivity
(%ID
/g)
* P<0.05 vs blood** P<0.01 vs blood
Chiellini et al, J Endocrinol 213:223, 2012
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
1 . 0 2 . 0 3 . 0 4 .0 5 .0 6 .0 T im e , m in0
2 . 0 e 5
4 . 0 e 5
Inte
nsity
, cps
3 . 0 9
D 4 -T 1A M
T 1 A M
1 . 0 2 . 0 3 . 0 4 .0 5 .0 6 .0 T im e , m in0
0 . 6 e 5
1 . 2 e 5
Inte
nsity
, cps
3 . 0 8
T 1A M D 4- T 1 A M
1 . 0 2 . 0 3 . 0 4 .0 5 .0 6 .0 T im e , m in0
2 . 0 e 5
4 . 0 e 5
Inte
nsity
, cps
3 . 0 9
D 4 -T 1A M
T 1 A M
1 . 0 2 . 0 3 . 0 4 .0 5 .0 6 .0 T im e , m in0
0 . 6 e 5
1 . 2 e 5
Inte
nsity
, cps
3 . 0 8
T 1A M D 4- T 1 A M A
B
human serum
rat liver
T1AM in human blood
Saba et al, Endocrinology 151:5063, 2010
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM in human blood
Galli et al, J Clin Endocrinol Metab 97:E69, 2012
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM assay in tissuesReference species tissue concentration
Scanlan et al, Nat Med 2004 rat brain < 1 pmol/g
Chiellini et al, FASEB J 2007 rat heart ≈ 68 pmol/g
Braulke et al, J Comp Physiol 2008 hamster blood 6 nM
Ackermans et al, J Endocrinol 2010 rat & human blood none (<0.25 nM)human thyroid none (<0.3 pmol/g)
Saba et al, Endocrinology 2010 rat many 0.3 – 92 pmol/g
Hoefig et al, JCEM, 2011 human blood 66 nM*
Galli et al, JCEM, 2012 human blood 0.2 nM
Hackenmuller et al, Endocrinology 2012 mouse liver 2 pmol/g
* immunological assay
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Messages to take home (1)
• T1AM can be detected in blood and in most tissues at nanomolarconcentrations.
• A few technical issues must still be solved before quantitative correlationsbetween blood T1AM and other clinical variables can be reliablyinterpreted.
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM as a chemical messenger
• found in brain and other tissues
• agonist of TAAR1• interacts with amine transporters• interacts with mitochondrial targets• interacts with apoB-100
• hypothermia• decreased cardiac contractility• decreased insulin secretion• increased gluconeogenesis• shift to lipid catabolism• neuromodulatory action• behavioral effects
• endogenous compound, which
• by acting on specific receptors
• produces functional effects
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Endocrine and metabolic effects of T1AM
Reference adm. dose effect
Braulke et al, J Comp Physiol 2007 ip 128 mol/Kg ↓ respiratory quotient, ↓ body fat
Regards et al, J Clin Invest 2007 ip 128 mol/Kg ↑ glucose, ↓ insulin, ↑ glucagon
Klieverik et al, J Endocrinol 2009 icv 1.2 mol/Kg ↑ glucose, ↑ glucagonip 128 mol/Kg ↑ glucose, ↑ glucagon
Manni et al, Br J Pharmacol 2012 icv 3.3 nmol/Kg ↑ glucose
Manni et al, Br J Pharmacol 2013 icv 0.3 nmol/Kg ↑ glucose
Haviland et al, Obesity 2013 ip 25 mol/kg/day ↓ body weight, lipolysis
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
-12
-10
-8
-6
-4
-2
0
2
4
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Bod
y w
eigh
t cha
nge
(%)
Study day
SHAMT1AM
Effects of chronic T1AM treatment on body weight
10 mg/Kg/day T1AM
Haviland et al, Obesity, 2013
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
p=0.0170 p=0.0166
p=0.0221
p=0.129
p=0.0121
p=0.162
p=0.152 p=0.140
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0 1 2 3 4 5 6 7
Study day
Aver
age
chan
ge in
13 C
va
lue
Effects of chronic T1AM treatment on lipid metabolism
Haviland et al, Obesity, 2013
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Glucose Lactate
Co
nc
en
trat
ion
(m
M)
•Control •Day 4 •Day 7
Metabolic effects of chronic T1AM treatment
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM and sirtuin expression in liver
qPCR
Western blot
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
•Lipolysis•Fatty Acid •Biosynthesis
•Cholesterol •Uptake
T1AM and gene expression in adipose tissue
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
liver WAT
control 24±8 0.5±0.2
T1AM (10 mg/Kg/day) 2041±119 -
T1AM (25 mg/Kg/day) 8513±1746 14.6±5.5
Assay of tissue T1AM (pmol/g)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
• Administration of exogenous T1AM decreases insulin secretion and/orproduces anti-insulin effects.
• Chronic administration of exogenous T1AM induces lipolysis anddecreases body weight. This likely involves complex modulation of geneexpression.
Messages to take home (2)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Gompf et al, Brain Res 1351:130, 2010
Neuromodulatory action of T1AM
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Behavioral effects of T1AM
Reference adm. dose effect
Dhillo et al, Diabetes Obes Metab 2009 icv 1.2 nmol/Kg ↑ food intakeip 4 nmol/Kg ↑ food intake
Manni et al, Br J Pharmacol 2012 icv 3.3 nmol/Kg ↓ food intake 51 nmol/Kg ↑ food intake
Haviland et al, Obesity 2013 ip 25 mol/kg/day = food intake
James et al, Horm Behav 2013 icv 10 nmol/kg nREM sleep reduction
Manni et al, Br J Pharmacol 2013 icv 3.3 nmol/Kg pro-learning effect1.0 nmol/Kg ↓ pain threshold
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
i.c.v. injection
15 min
Training
1 hour
Acquisition
24 hours
Retention
MS assay of T1AM/TA1Western blot for pERK
mouse
Effect of T1AM on learning
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Pro-learning effect of T1AM
Manni et al, Br J Pharmacol 168:354, 2013
0
100
200
300
400
Ste
p-th
roug
h la
tenc
y (s
ec)
Training Acquisition (1 h) Retention (24 h)
P<0.05 vs vehicle
P<0.01 vs vehicle
VehicleT1AM 0.13 g/Kg
T1AM 0.4 g/Kg
T1AM 1.32 g/KgT1AM 4 g/Kg
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
Anti-amnestic effect of T1AM
0
100
200
300
Vehicle + scop.Vehicle
*
scopolamine
T1AM 0.4 g/Kg + scopT1AM 1.32 g/Kg + scop
Training Acquisition (1 h) Retention (24 h)
**
* P<0.05 vs vehicle
** P<0.01 vs vehicle
scopolaminescopolamine
*
§§ P<0.01 vs vehicle + scop
§§*
§§ §§ §§
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
• Mesencephalon
•T1AM (gkg-1)
•Amygdala
•Hippocampus
•0.044 •0.132•Veh.
•α-tubulin•p-ERK 1/2
•Hypothalamus
•Veh. •0.044 •0.132
•T1AM (gkg-1)
ERK activation by T1AMp/
ER
K 2
exp
ress
ion
(Arb
irary
Uni
ts)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
T1AM TA1
Baseline 48.6±17.7 0.8±0.2
Vehicle 33.6±6.0 0.7±0.3
T1AM icv (1.32 g/Kg) 1008.6±313.0 22.2±4.8
Brain assay for T1AM and TA1 (pmol/g)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)
• Intracerebral administration of T1AM has pro-learning and anti-amnesticeffects, at doses increasing endogenous concentration by about oneorder of magnitude.
• T1AM might have physiological and/or pathophysiological importance inthe regulation of metabolism and of CNS function.
Messages to take home (3)
PRESENTATION FROM THE 83rd ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION, OCTOBER 16-20, 2013 (Riccardo Zucchi)